Camel milk hypoglycemic peptide with DPP-IV and SGLT-2 inhibitory activity and application

By preparing and applying the endogenous hypoglycemic peptide of camel milk with DPP-IV and SGLT-2 inhibitory activity, the problems of insulin resistance and high-fat diet induced fat accumulation were solved, significantly improved blood sugar and blood lipid levels, and increased glucose consumption and Glycogen synthesis capability.

CN118955611AInactive Publication Date: 2024-11-15CHINA AGRI UNIV +1

Patent Information

Application Number
CN202411448257.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-17
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve insulin resistance and high-fat diet-induced fat accumulation, and there is a lack of effective methods for inhibitory activities of DPP-IV and SGLT-2.

Method used

By preparing endogenous hypoglycemic peptides of camel milk with DPP-IV and SGLT-2 inhibitory activities, the specific methods include defacing, adjusting pH, ultrafiltration centrifugation and peptide sequence analysis of raw camel milk, screening out polypeptide sequences such as AGF and MPL. and is used in the treatment and prevention of insulin resistance.

Benefits of technology

Significantly reduced serum insulin, blood sugar and glycated hemoglobin levels, improved liver damage and blood lipid levels in mice, reduced total triglycerides and total cholesterol content in serum and liver, improved glucose consumption and glycogen synthesis capacity, and improved Symptoms of insulin resistance and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955611A_ABST
    Figure CN118955611A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of dairy products, and particularly relates to preparation and application of camel milk hypoglycemic peptide with DPP-IV and SGLT-2 inhibitory activity. The invention provides a preparation method of a hypoglycemic peptide taking camel milk as a raw material, and camel milk endogenous peptide sequences, including AGF and MPL, capable of inhibiting DPP-IV and SGLT-2 are screened by adopting a molecular docking method. In-vitro HepG2 hepatocytes prove that the camel milk endogenous peptide can improve insulin-resistant uptake, and glucose is used for synthesizing glycogen; the in-vivo level proves that the camel milk endogenous peptide has a certain improvement effect on insulin-resistant mice, and also has the effect of inhibiting the expression of DPP-IV and SGLT-2. Therefore, the camel milk endogenous peptide obtained by the invention has hypoglycemic activity, can relieve insulin resistance diseases, provides a scientific basis for development of health-care foods and medicines with a blood sugar regulating effect and industrial production, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of dairy products, and particularly relates to a preparation method and application of a camel milk hypoglycemic peptide with DPP-IV and SGLT-2 inhibitory activity. Background Art

[0002] Insulin resistance is a common feature of a series of metabolic diseases, such as metabolic disorders such as obesity, type 2 diabetes, hypertension, and non-alcoholic fatty liver disease. Insulin resistance (IR) refers to the weakening of the efficacy of insulin in the body, and the decrease in the responsiveness (maximum effect of insulin) or sensitivity (insulin concentration required for half-maximum response) of tissues to normal levels of insulin metabolism. This leads to a decrease in the glucose uptake capacity of the main insulin action tissues (liver, muscle, and adipose tissue) and the activation of the gluconeogenesis process.

[0003] Dipeptidyl peptidase-IV (DPP-IV) is a ubiquitously expressed 110 kDa serine protease. DPP-IV can inactivate a variety of bioactive peptides, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-IV inhibitors inactivate DPP-IV and increase the expression levels of GLP-1 and GIP, thereby exerting their function of controlling blood sugar.

[0004] Sodium-glucose co-transporter (SGLT) is an important co-transporter in the renal tubules, which transports glucose into the cell via the sodium ion gradient across the cell membrane to provide energy for the cell. SGLT-2 inhibitors inhibit the reabsorption of glucose by the kidneys, allowing glucose to be excreted from the body through urine, thereby lowering the body's blood sugar level. While lowering blood sugar levels, SGLT-2 inhibitors can also help reduce weight, lower blood pressure, reduce kidney inflammation, slow down dyslipidemia, slow down liver fibrosis, reduce the development of insulin resistance, and reduce cardiovascular disease.

[0005] The invention utilizes camel milk endogenous peptides with DPP-IV and SGLT-2 inhibitory activities to improve insulin resistance and fat accumulation induced by a high-fat diet and reduce body weight. Summary of the invention

[0006] In view of the shortcomings of the prior art, the present invention aims to propose a method for improving insulin resistance. By preparing endogenous peptides from camel milk, polypeptides with DPP-IV inhibitory activity and / or SGLT-2 inhibitory activity are obtained, thereby solving the problems caused by insulin resistance.

[0007] To achieve the above object, on the one hand, the present invention provides two camel milk endogenous hypoglycemic peptides with hypoglycemic effect, and their amino acid sequences are: AGF (SEQ ID NO.1) and MPL (SEQ ID NO.2).

[0008] In a second aspect, the present invention provides a method for preparing camel milk endogenous hypoglycemic peptide, which is prepared by the following method: (1) Raw camel milk was centrifuged at 4000 g and 4°C for 20 min, and the intermediate sample was taken to obtain skimmed camel milk; (2) The pH of skimmed camel milk was adjusted to 4.6 with 1 M HCl, and after standing at 4°C for 10 min, the solution was centrifuged at 4000 g for 10 min, and the supernatant was collected to obtain camel milk whey; (3) ultrafiltration and centrifugation of camel milk whey to obtain endogenous peptides for freeze-drying and storage; (4) Performing peptide sequence analysis on the camel milk endogenous peptides to obtain the polypeptide sequences in the endogenous peptides.

[0009] In a third aspect, the present invention provides a composition comprising at least one or two of AGF (SEQ ID NO.1) and MPL (SEQ ID NO.2).

[0010] In a fourth aspect, the present invention also provides the use of camel milk endogenous glucose-lowering peptides in insulin resistance, specifically, the use of camel milk endogenous glucose-lowering peptides in the preparation of health foods that help control body fat, help maintain healthy blood lipid levels, help maintain healthy blood sugar levels, and help maintain healthy blood pressure levels.

[0011] Specifically, the application of camel milk endogenous glucose-lowering peptides in the preparation of products for preventing and / or treating diabetes, obesity, insulin resistance, and non-alcoholic fatty liver disease.

[0012] Specifically, the application of camel milk endogenous hypoglycemic peptide composition in products for improving insulin resistance.

[0013] Compared with the prior art, the present invention has the following advantages: (1) The present invention provides a method for efficiently utilizing camel milk whey, which provides a basis for the comprehensive utilization of camel milk whey and has high social significance and economic value.

[0014] (2) Based on the identification of the amino acid sequence of camel milk endogenous peptides, the present invention uses a molecular docking method to screen and obtain a total of four camel milk endogenous peptide sequences with the ability to inhibit DPP-Ⅳ and SGLT-2 activity, namely AGF (SEQ ID NO.1), MPL (SEQ ID NO.2), PPL (SEQ ID NO.3), and FPVG (SEQ ID NO.4), which greatly reduces the workload of experimental verification and improves the accuracy of specific function screening.

[0015] (3) The present invention proposes that the amino acid sequences of AGF and MPL have an effective improvement effect on insulin-resistant HepG2 cells and promote glucose consumption to synthesize glycogen.

[0016] (4) The present invention confirms that the amino acid sequences of AGF and MPL have the ability to reduce serum insulin, blood glucose, and glycosylated hemoglobin levels in mice with insulin resistance induced by a high-fat diet, improve the level of chronic inflammation in mice, reduce the total triglyceride and total cholesterol content in the serum and liver of mice, and improve liver damage in mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Molecular docking diagram of peptide AGF and DPP-IV.

[0018] Figure 2 Molecular docking diagram of peptide MPL and DPP-IV.

[0019] Figure 3 Molecular docking diagram of peptide PPL and DPP-IV.

[0020] Figure 4 Molecular docking diagram of peptide FPVG and DPP-IV.

[0021] Figure 5 Molecular docking diagram of peptide AGF and SGLT-2.

[0022] Figure 6 Molecular docking diagram of peptide MPL and SGLT-2.

[0023] Figure 7 Molecular docking diagram of peptide PPL and SGLT-2.

[0024] Figure 8 Molecular docking diagram of peptide FPVG and SGLT-2.

[0025] Fig. 9 Effects of camel milk endogenous peptides on glucose consumption in insulin-resistant HepG2 cells (Different lowercase letters indicate significant differences among the groups. p <0.05).

[0026] Fig.10 Effects of camel milk endogenous peptides on glycogen synthesis in insulin-resistant HepG2 cells (Different lowercase letters indicate significant differences among the groups. p <0.05).

[0027] Fig.11 Effect of camel milk endogenous peptides on body weight changes in insulin-resistant mice during intervention.

[0028] Fig.12 Effect of camel milk endogenous peptides on food intake in insulin-resistant mice during intervention.

[0029] Fig.13 Effects of camel milk endogenous peptides on oral glucose tolerance (OGTT) in insulin-resistant mice.

[0030] Fig.14 Quantification of the area under the OGTT curve (AUC) of camel milk endogenous peptides in insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0031] Fig.15 Effects of camel milk endogenous peptides on intraperitoneal insulin tolerance test (IPITT) in insulin-resistant mice.

[0032] Fig.16 Quantification of the area under the IPITT curve (AUC) of camel milk endogenous peptides in insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0033] Fig.17 Fasting insulin levels in insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05).

[0034] Fig.18 Fasting blood glucose in insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05).

[0035] Fig.19 Fasting glycosylated hemoglobin levels in insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05).

[0036] Fig. 20 Pathological tissue sections of liver in mice with insulin resistance after intervention with camel milk endogenous peptides.

[0037] Fig.21The serum total triglyceride (TG) level of camel milk endogenous peptides in insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0038] Fig. 22 The serum total cholesterol (TC) level of camel milk endogenous peptides in insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0039] Fig.23 The serum low-density lipoprotein (LDL-C) level of camel milk endogenous peptides in insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0040] Fig.24 The total triglyceride (TG) level in the liver of insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05).

[0041] Fig.25 Camel milk endogenous peptides intervened in the liver total cholesterol (TC) level of insulin-resistant mice (different lowercase letters indicate significant differences among the groups, p <0.05).

[0042] Fig.26 Serum DPP-IV levels in insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05).

[0043] Fig. 27 The level of SGLT-2 mRNA in the kidney of insulin-resistant mice after intervention with camel milk endogenous peptides (different lowercase letters indicate significant differences among the groups, p <0.05). DETAILED DESCRIPTION

[0044] The following is a further description of the concept of the present invention and the technical effects produced in conjunction with specific embodiments, so as to fully understand the purpose, features and effects of the present invention. The methods are conventional methods unless otherwise specified. The materials can be obtained from public commercial channels unless otherwise specified. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations of the present invention. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

[0045] Example 1: Preparation of camel milk endogenous peptides with the effects of improving insulin resistance and lowering blood sugar In this embodiment, camel milk endogenous peptides having the effects of improving insulin resistance and lowering blood sugar activity were prepared by the following method: (1) Raw camel milk was centrifuged at 4000 g and 4°C for 20 min, and the intermediate sample was taken to obtain skimmed camel milk; (2) The pH of skimmed camel milk was adjusted to 4.6 with 1 M HCl, and after standing at 4°C for 10 min, the solution was centrifuged at 4000 g for 10 min, and the supernatant was collected to obtain camel milk whey; (3) ultrafiltration and centrifugation of camel milk whey to obtain endogenous peptides for freeze-drying and storage; (4) Performing peptide sequence analysis on the camel milk endogenous peptides to obtain the polypeptide sequences in the camel milk endogenous peptides.

[0046] Example 2: Identification of amino acid sequences of camel milk endogenous peptides (1) Desalting: Further desalting was performed using a C18 column. The C18 column was activated with 1.5 mL of methanol and then equilibrated with 1.5 mL of 0.1% (V / V) TFA-H2O solution. The camel milk endogenous peptides were redissolved with 0.1% (V / V) TFA-H2O solution and added to the C18 column. The peptides were eluted with 1.5 mL of 80% (V / V) ACN / 0.1% (V / V) TFA-H2O solution. The eluate was collected and its peptide concentration was measured for TripleTOF™6600+MS analysis.

[0047] (2) Peptide sequence identification: Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI MS / MS) was used to identify the peptide sequence. Camel milk was dissolved in 0.1% formic acid solution and analyzed by Orbitrap Q-Exactive Plus mass spectrometer. The sample was separated by a 60-min gradient. The column flow rate was 300 nL / min, the column temperature was 40°C, and the electrospray voltage was 2 kV. The chromatographic gradient was as follows (A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile): The gradient started from 2% of phase B, increased to 35% in a nonlinear gradient at 47 min, increased to 100% within 1 min, and maintained for 12 min. The mass spectrometry parameters were set as follows: (1) MS: scan range (m / z) = 200–2000; resolution = 70,000; AGC target = 3e6; maximum injection time = 50 ms; (2) HCD-MS / MS: resolution = 17,500; AGC target = 1e5; maximum injection time = 45 ms; collision energy: 28%; dynamic exclusion time: 30 s.

[0048] (3) The obtained peptide data were compared with the UniProt and NCBI databases to identify the amino acid sequence of camel milk endogenous peptides.

[0049] Example 3: Screening of synthetic peptides for potential DPP-IV inhibitory peptides and SGLT-2 inhibitory peptides PeptideRanker was used to evaluate the potential biological activity of the peptides. The value range of this program is 0 to 1, with a threshold of 0.8. The top high-affinity peptides were retained by comprehensively considering the peptide-protein binding energy and homology as well as the appropriate length of the peptide. Table 1 shows the peptide sequences with DPP-Ⅳ docking scores higher than 0.8. Table 2 shows the peptide sequences with SGLT-2 docking scores higher than 0.8.

[0050] According to the docking energy between camel milk endogenous peptides and key proteins of insulin resistance, four polypeptides were screened out from the identified peptides, namely AGF (SEQ ID NO.1), MPL (SEQ ID NO.2), PPL (SEQ ID NO.3), and FPVG (SEQID NO.4). Figure 1-4 This is the docking diagram of four peptides and DPP-IV. Figure 5-8 This is the docking diagram of four peptides and SGLT-2.

[0051] The active peptides provided by the present invention are derived from endogenous peptides of camel milk and can also be obtained by solid phase synthesis. The peptide segments AGF (SEQ ID NO.1), MPL (SEQ ID NO.2), PPL (SEQ ID NO.3), and FPVG (SEQ ID NO.4) used in the following examples are obtained by solid phase synthesis. Shanghai Nuoyou Biotechnology Co., Ltd. was commissioned to solid phase synthesize the above-mentioned hypoglycemic peptide segments for subsequent experiments.

[0052] Table 1 Docking energy of camel active peptides and DPP-Ⅳ protein

[0053] Table 2 Docking energy of camel active peptides and SGLT-2 protein

[0054] Example 4: Determination of in vitro glucose absorption rate and glycogen synthesis rate of peptide fragments By constructing insulin-resistant HepG2 cells, the effects of the peptides on glucose utilization and glycogen synthesis in insulin-resistant liver cells were evaluated. The specific steps are as follows: 200 μL of cell suspension was added to each well of a 96-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h to establish an insulin resistance model. 10 μL of sample solution was added to the experimental group, and 10 μL of PBS was added to the blank group. After 24 h, the culture medium in the 96-well plate was aspirated for the determination of glucose absorption rate. The glucose absorption rate was determined using a glucose oxidase detection kit (Nanjing Jiancheng Bioengineering Institute, A154-1-1).

[0055] 2 mL of cell suspension was added to each well of a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h to establish an insulin resistance model. 100 μL of sample solution was added to the experimental group, and 100 μL of PBS was added to the blank group. Cellular glycogen content was determined using a glycogen kit (Nanjing Jiancheng Bioengineering Institute, A043-1-1).

[0056] Compared with the normal group, the glucose consumption of the model group decreased by 66.7%, and the intracellular glycogen content decreased by 38.63%, indicating that the insulin resistance model of HepG2 cells was successfully established. The camel milk endogenous peptides AGF, MPL, PPL, and FPVG with high DPP-IV and SGLT-2 docking energy in molecular docking were synthesized in vitro and verified for their insulin resistance effect on HepG2. Fig. 9 It can be seen that camel milk endogenous peptides can effectively improve the insulin resistance of HepG2 cells, among which AGF and MPL had the best intervention effects, which increased by 133.11% and 116.07% respectively compared with the model group. Fig.10 It can be seen that camel milk can effectively improve the glycogen synthesis capacity of HepG2 cells, among which AGF and MPL had the best intervention effects, which increased by 45.24% and 41.79% respectively compared with the model group.

[0057] Example 5: Effect of camel milk endogenous peptides on improving insulin resistance in mice fed a high-fat diet According to Examples 2, 3, and 4, peptides AGF and MPL have good hypoglycemic effects and can promote glucose uptake and storage in vitro. Animal experiments were conducted using camel milk endogenous peptides to study their hypoglycemic effects in vivo.

[0058] Male C57BL / 6J mice aged 5 weeks (35-41 days) were purchased from Beijing Weitong Lihua Experimental Technology Co., Ltd., license number: SCXK (Beijing) 2021-0011, use license number: SYXK (Beijing) 2020-0037. They were raised in accordance with the SPF animal husbandry standards. The animal experiments were reviewed and approved by the Animal Experiment Committee of China Agricultural University, and the ethical review number is KY160049. The laboratory environment was stable, with a temperature of 22 ± 1℃, a humidity of 40 ± 10%, a pressure difference of 20-50 Pa, and a light-dark cycle of 12h. After 1 week of adaptation, the mice were randomly divided into a normal diet (ND) group (n=6) and a high-fat diet (HFD) group (n=24). The mice in the ND group were fed a normal diet, and the mice in the HFD group were fed a high-fat diet for 10 weeks to construct high-fat diet-induced insulin resistance mice. After 10 weeks, fasting blood glucose, fasting insulin and glycosylated hemoglobin levels were measured, and the insulin resistance index (HOMA-IR) was calculated. The insulin resistance index of mice in the HFD group was greater than 2.69, indicating that the high-fat diet-induced insulin resistance model was successfully established. The high-fat diet mice were randomly divided into HFD group, AGF group, MPL group and metformin group (HFDMet group), with 6 mice in each group. The corresponding intervention substances were given for nine weeks, and the food intake and body weight of the mice were measured every week during the intervention period.

[0059] The weight changes of mice were monitored during the intervention period to explore the improvement effect of the application example of the present invention on high-fat diet-induced obesity. Fig.11 As shown in the figure, compared with the ND group, the weight of mice in the HFD group increased significantly, and the weight gain trend increased with the intervention time. The intervention of AGF and MPL groups can significantly reduce the obesity caused by high-fat diet and reduce the weight of mice. The food intake of mice was measured every three days. The results are shown in the figure. Fig.12 This indicates that the improvement of insulin resistance caused by AGF and MPL intervention is not due to reduced food intake.

[0060] After 8 weeks of intervention, the mice were fasted but not watered for 12 h, and were gavaged with glucose at a dose of 2 g / kg BW. Blood was collected from the tail tip of the mice at 0, 30, 60, 90, and 120 min after gavage. Blood glucose levels were measured with a blood glucose meter, and the curve was drawn to calculate the area under the curve (AUC).

[0061] like Figure 13-14As shown in the figure, the blood glucose of mice increased after oral administration of glucose and reached the maximum at 30 min, and tended to be flat at 90 min after oral administration. Compared with the ND group, the blood glucose of HFD mice was still at a high level at 120 min after oral administration of glucose, and the area under the curve (AUC) during the OGTT test was 1.68 times that of the ND group. This shows that the glucose tolerance of mice induced by high-fat diet was impaired and the ability to regulate blood glucose decreased. The intervention of camel milk endogenous peptides and metformin effectively improved the blood glucose regulation ability of insulin-resistant mice and had a good improvement effect on the glucose tolerance impairment induced by high-fat diet. The glucose-lowering peptides AGF and MPL decreased the AUC of HFD mice by 18.49% and 22.21%, respectively. Metformin intervention decreased the AUC of HFD mice by 14.68%. The above results show that camel milk endogenous peptides can improve the impaired glucose tolerance of insulin-resistant mice and improve the blood glucose regulation ability of mice fed a high-fat diet.

[0062] After 9 weeks of intervention, insulin (0.75 U / kg bw) was injected intraperitoneally. Blood glucose levels were measured by tail tip blood sampling before (0 min) and 30 min, 60 min, 90 min, and 120 min after insulin injection, and curves were drawn to calculate the area under the curve (AUC).

[0063] like Figure 15-16 As shown in the figure, after intraperitoneal injection of insulin, the blood glucose level of mice dropped rapidly. Blood glucose gradually recovered 90 minutes after intraperitoneal injection. Compared with the ND group, the blood glucose of mice in the HFD group dropped more slowly after insulin injection, and the area under the curve (AUC) increased significantly, which was 1.61 times that of the ND group, indicating that the insulin sensitivity of mice was impaired due to high-sugar and high-fat diet. Camel milk endogenous peptides and metformin significantly increased the rate of blood glucose decline in insulin-resistant mice. Camel milk endogenous peptides AGF and MPL significantly improved the impaired insulin tolerance of insulin-resistant mice, reducing the AUC of insulin mice by 15.93% and 25.24%, respectively. Metformin intervention reduced the AUC of HFD mice by 25.90%. It shows that camel milk endogenous peptides effectively improve the insulin tolerance of HFD mice and alleviate the degree of insulin resistance in mice.

[0064] The fasting insulin, fasting blood glucose and glycosylated hemoglobin of mice were measured to explore the effect of the application example of the present invention on the indicators in the serum of insulin-resistant mice induced by a high-fat diet. Figure 17-19As shown in the figure, compared with the ND group, the fasting insulin, fasting blood glucose, and glycosylated hemoglobin levels of HFD mice were significantly increased, indicating that the high-fat diet induced diabetes and insulin resistance in mice. After intervention with the glucose-lowering peptides AGF and MPL, the fasting insulin levels of insulin-resistant mice were significantly reduced by 22.64% and 19.10%, respectively; after intervention with the glucose-lowering peptides AGF and MPL, the fasting blood glucose levels of insulin-resistant mice were significantly reduced by 20.62% and 17.66%, respectively, and the results after intervention were not significantly different from those of the metformin positive drug group; after intervention with the glucose-lowering peptides AGF and MPL, the fasting blood glucose levels of insulin-resistant mice were significantly reduced by 31.98% and 26.14%, respectively.

[0065] Mouse liver tissue was taken for H&E staining to explore the effect of the application example of the present invention on lipid accumulation and liver damage induced by a high-fat diet. Fig. 20 As shown in the figure, compared with the ND group, the lipid droplets in the liver tissue of HFD mice increased and the balloon-like lesions were severe, indicating that the high-fat diet induced lipid accumulation in mice. The intervention of hypoglycemic peptides AGF and MPL significantly reduced the lipid droplet accumulation in liver cells and the degree of liver damage, indicating that camel milk endogenous peptides have an improvement effect on reducing lipid accumulation and alleviating liver damage.

[0066] The total triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the mouse serum were measured to characterize the blood lipid level of the mouse. Figure 21-23 As shown. After intervention with the glucose-lowering peptides AGF and MPL, the serum TG level decreased significantly, by 11.79% and 18.76%, respectively; the serum TC level improved significantly after intervention with the glucose-lowering peptides AGF and MPL, by 25.70% and 10.59%, respectively; the serum TC level improved significantly after intervention with the glucose-lowering peptides AGF and MPL, by 35.85% and 26.34%, respectively, indicating that the intervention with endogenous camel milk peptides can effectively improve the blood lipid level of insulin-resistant mice and alleviate their lipid deposition.

[0067] The levels of total triglyceride (TG) and total cholesterol (TC) in mouse liver were measured. Figure 24-25 As shown. After intervention with the glucose-lowering peptides AGF and MPL, the levels of total triglyceride and total cholesterol in the liver decreased significantly, with triglyceride decreasing by 35.92% and 24.43% respectively compared with the HFD group; total cholesterol decreased by 42.81% and 30.29% respectively compared with the HFD group, indicating that peptide intervention significantly improved the liver lipid level and liver lipid accumulation in mice fed a high-fat diet.

[0068] The activity of DPP-IV in mouse serum was measured. Fig.26As shown in the figure, the serum DPP-IV activity level decreased significantly after intervention with the glucose-lowering peptides AGF and MPL, which decreased by 40.67% and 32.18%, respectively, indicating that the peptide intervention played a role in inhibiting DPP-IV activity.

[0069] The mRNA expression of SGLT-2 in mouse kidney was measured. Fig. 27 As shown in the figure, the relative mRNA expression of SGLT-2 in the kidney decreased significantly after intervention with the glucose-lowering peptides AGF and MPL, which decreased by 50.51% and 53.57%, respectively, indicating that the peptide intervention played a role in inhibiting renal glucose reabsorption and improving insulin resistance.

[0070] The embodiments described above are only some embodiments of the present invention, rather than all embodiments. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work shall all fall within the scope of protection of the present invention.

Claims

1. A camel milk endogenous hypoglycemic peptide having hypoglycemic effect, characterized in that: The amino acid sequence of the camel milk endogenous hypoglycemic peptide is: AGF, as shown in SEQ ID NO.

1.

2. A camel milk endogenous hypoglycemic peptide having hypoglycemic effect, characterized in that: The amino acid sequence of the camel milk endogenous hypoglycemic peptide is: MPL, as shown in SEQ ID NO.

2.

3. The camel milk endogenous hypoglycemic peptide according to any one of claims 1 or 2, characterized in that: The invention has one or more of SGLT-2 inhibitory activity and DPP-IV inhibitory activity, and can improve insulin resistance diseases.

4. A method for preparing the camel milk endogenous hypoglycemic peptide according to any one of claims 1 to 3, characterized in that: Prepared by the following method: (1) Raw camel milk was centrifuged at 4000 g and 4°C for 20 min, and the intermediate sample was taken to obtain skimmed camel milk; (2) The pH of skimmed camel milk was adjusted to 4.6 with 1 M HCl, and after standing at 4°C for 10 min, the solution was centrifuged at 4000 g for 10 min, and the supernatant was collected to obtain camel milk whey. (3) ultrafiltration and centrifugation of camel milk whey to obtain endogenous peptides for freeze-drying and storage; (4) performing peptide sequence analysis on the endogenous peptides to obtain the polypeptide sequences in the camel milk endogenous peptides.

5. The preparation method according to claim 4, characterized in that: The peptide sequences were identified by liquid chromatography-electrospray ionization tandem mass spectrometry.

6. A composition, characterized in that Contains one or more of the camel milk endogenous hypoglycemic peptides described in any one of claims 1-2.

7. Use of the composition as claimed in claim 6 in preparing a product that helps control body fat, helps maintain healthy blood lipid levels, helps maintain healthy blood sugar levels, and helps maintain healthy blood pressure levels.

8. Use of the composition according to claim 6 in preparing a product for preventing and / or treating diabetes, obesity, insulin resistance, and non-alcoholic fatty liver disease.

9. Use of the camel milk endogenous hypoglycemic peptide as claimed in any one of claims 1 or 2 in the preparation of health food that helps control body fat, helps maintain healthy blood lipid levels, helps maintain healthy blood sugar levels, and helps maintain healthy blood pressure levels.

10. Use of the camel milk endogenous glucose-lowering peptide according to any one of claims 1 or 2 in the preparation of products for preventing and / or treating diabetes, obesity, insulin resistance, and non-alcoholic fatty liver disease.

Citation Information

Patent Citations

  • Bioactive peptide for inhibiting dipeptidyl peptidase-4 and preparation method and application thereof

    CN106905416A

  • Method for designing DPP-IV (dipeptidyl peptidase-IV) inhibitory peptide by computer-aided drug, DPP-IV inhibitory peptide and application thereof

    CN113035291A

  • Application of camel milk protein source polypeptide LLPK in preparation of health-care products for assisting in reducing blood sugar

    CN116421701A

  • GIP / GLP1 dual agonist therapeutic methods

    CN117320740A

  • Inhibitors of Amyloid Fibril Formation and Uses Thereof

    US20080004211A1

Cited By

  • Camel milk-derived immunoactive peptide for adjuvant therapy of tumors as well as extraction method and application of camel milk-derived immunoactive peptide

    CN120484058A